Edwards Lifesciences Corporation (EW) Stock Forecast
EW analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.41 / 5 from 29 analysts
- Price target
- $101.81 average of analyst targets
- Upside to target
- +17.6% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $0.73
- 52-week range
- $75.29 – $95.18
EW analyst ratings
29 analystsNumber of analysts at each rating.
EW price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
EW earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.74 | $0.72 | $0.77 | $0.67 | +9.9% | 24 |
| Current fiscal year (2026) | $3.00 | $2.96 | $3.05 | $2.56 | +17.2% | 28 |
| Next fiscal year (2027) | $3.38 | $3.29 | $3.50 | $3.00 | +12.8% | 28 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
EW revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.68B | $1.65B | $1.71B | +8.0% | 24 |
| Current fiscal year (2026) | $6.76B | $6.66B | $6.84B | +11.5% | 27 |
| Next fiscal year (2027) | $7.43B | $7.22B | $7.66B | +9.9% | 27 |
EW EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
EW revenue: reported and forecast
EW EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.75 | $0.74 | $0.74 | $0.74 | $0.74 | −1.3% | 2 up · 15 down |
| Current fiscal year (2026) | $3.01 | $3.00 | $3.00 | $3.00 | $3.00 | −0.2% | 1 up · 0 down |
| Next fiscal year (2027) | $3.36 | $3.38 | $3.38 | $3.38 | $3.38 | +0.6% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
EW earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; EW beat in 11 of 12.
What analysts expect from EW
29 analysts cover Edwards Lifesciences; their consensus rating is buy (4.41 on a 1–5 scale, where 5 is a strong buy). The average price target is $101.81, 17.6% above the latest close of $86.60. Analysts expect earnings of $3.00 per share for 2026, +17.2% from a year earlier. For 2027 the average estimate is $3.38 per share on revenue of $7.4 billion. Edwards Lifesciences beat the EPS estimate in 11 of the last 12 quarters.
Related: EW income statement, EW key metrics, EW chart. See the EW stock overview for the latest quote and news.
EW forecast FAQ
What is Edwards Lifesciences's price target?
The average analyst price target for Edwards Lifesciences is $101.81, 17.6% above the latest close of $86.60.
Is Edwards Lifesciences a buy, hold or sell?
Of 29 analysts covering Edwards Lifesciences, 18 rate it a strong buy, 5 a buy, 6 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Edwards Lifesciences's EPS forecast?
Analysts forecast $3.00 per share for 2026 (range $2.96 to $3.05); for 2027 the estimate is $3.38.
What is Edwards Lifesciences's revenue forecast?
The average revenue estimate for 2026 is $6.8 billion, growth of 11.5%; for 2027 it is $7.4 billion.
When does Edwards Lifesciences report earnings?
Edwards Lifesciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes; the EPS estimate is $0.73.
Does Edwards Lifesciences usually beat earnings estimates?
Edwards Lifesciences reported EPS at or above the analyst estimate in 11 of the last 12 quarters.